Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans

Immunology and Cell Biology

Volumn 90, Issue 2, 2012, Pages 149-158

  Lynch, Garry W ^a   Selleck, Paul ^b   Church, W Bret ^a   Sullivan, John S ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CSIRO   (Australia)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

antibody; H5N1; heterosubtypic; influenza; pandemic; vaccine

Indexed keywords

INFLUENZA VACCINE;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; CROSS PROTECTION; HUMAN; HUMORAL IMMUNITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC INFLUENZA; REVIEW;

ADAPTIVE IMMUNITY; ANTIBODIES, VIRAL; CROSS PROTECTION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS;

AVES;

EID: 84857030922     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.38     Document Type: Review

References (124)

1. Fraser C, Donnelly CA, Cauchemez S, HanageWP, Van Kerkhove MD, Hollingsworth TD et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324: 1557-1561.
2. Morens DM, Taubenberger JK, Fauci AS. The persistent legacy of the 1918 influenza virus. New Engl J Med 2009; 361: 225-229.
3. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009; 459: 1122-1125.
4. Allen JE, Gardner SN, Vitalis EA, Slezak TR. Conserved amino acid markers from past influenza pandemic strains. BMC Microbiol 2009; 9: 77.
5. Sorrell EM, Wan H, Araya Y, Song H, Perez DR. Minimal molecular constraints for respiratory droplet transmission of an avian-human H9N2 influenza A virus. Proc Natl Acad Sci USA 2009; 106: 7565-7570.
6. Jackson S, Van Hoeven N, Chen LM, Maines TR, Cox NJ, Katz JM et al. Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. J Virol 2009; 83: 8131-8140.
7. Li C, Hatta M, Nidom CA, Muramoto Y, Watanabe S, Neumann G et al. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc Natl Acad Sci USA 2010; 107: 4687-4692.
8. McKibben WJ, Sidorenko AA. Global Macroeconomic Consequences of Pandemic Influenza. February Analysis. Lowy Institute for International Policy, 2006, pp 1-79.
9. Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C et al. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009; 27: 2099-2107.
10. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson IA. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 2004; 303: 1866-1870.
11. Xu R, McBride R, Paulson JC, Basler CF, Wilson IA. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol 2010; 84: 1715-1721.
12. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006; 312: 404-410.
13. Xu R, Ekiert DC, Krause JC, Hai R, Crowe Jr JE, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010; 328: 357-360.
14. Wright PF, Webster RG. Orthomyxoviruses. In: Knipe DM, Howley PM (eds). Fields Virology, 4th edn. Lippincott: Philadelphia, 2001, pp 1533-1579.
15. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 2008; 82: 5161-5166. (Pubitemid 351705225)
16. Richard SA, Viboud C, Miller MA. Evaluation of Southern Hemisphere influenza vaccine recommendations. Vaccine 2010; 28: 2693-2699.
17. Gong J, Fang H, Li M, Liu Y, Yang K, Liu Y et al. Potential targets and their relevant inhibitors in anti-influenza fields. Curr Med Chem 2009; 16: 3716-3739.
18. Gong J, Xu W, Zhang J. Structure and functions of influenza virus neuraminidase. Curr Med Chem 2007; 14: 113-122. (Pubitemid 46050308)
19. Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004; 64: 2031-2046. (Pubitemid 39280372)
20. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983; 37: 529-549.
21. Layne SP, Monto AS, Taubenberger JK. Pandemic influenza: an inconvenient mutation. Science 2009; 323: 1560-1561.
22. Palese P, Tumpey TM, Garcia-Sastre A. What can we learn from reconstructing the extinct 1918 pandemic influenza virus? Immunity 2006; 24: 121-124. (Pubitemid 43214579)
23. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006; 12: 15-22.
24. Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, Chiappini R et al. Crosssubtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008; 14: 121-128.
25. Schulman JL, Kilbourne ED. Induction of partial specific heterotypic immunity in mice by a single infection with influenza a virus. J Bacteriol 1965; 89: 170-174.
26. Howe HA. Studies of active immunogenesis in poliomyelitis. I. Persistence and recall by homotypic or heterotypic superinfection of neutralizing antibody originally induced in chimpanzees by vaccination or infection. Am J Hyg 1954; 60: 371.
27. Burlington DB, Wright PF, van Wyke KL, Phelan MA, Mayner RE, Murphy BR. Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol 1985; 21: 847-849. (Pubitemid 15093154)
28. Epstein SL. Control of influenza virus infection by immunity to conserved viral features. Expert Rev Anti-Infect Ther 2003; 1: 627-638. (Pubitemid 38855127)
29. Grebe KM, Yewdell JW, Bennink JR. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect Institut Pasteur 2008; 10: 1024-1029.
30. Lynch GW, Selleck PW, Axell A-M, Downton T, Kapitza N, Boehm I et al. Cross-reactive anti-avian H5N1 influenza neutralizing antibodies in a normal 'Exposure-Naïve' Australian blood donor population. Open Immunol J 2008; 1: 13-19.
31. Reid AH, Fanning TG, Janczewski TA, Taubenberger JK. Characterization of the 1918 'Spanish' influenza virus neuraminidase gene. Proc Natl Acad Sci USA 2000; 97: 6785-6790.
32. Sullivan JS, Selleck PW, Downton T, Boehm I, Axell AM, Ayob Y et al. Heterosubtypic anti-avian H5N1 influenza antibodies in intravenous immunoglobulins from globally separate populations protect against H5N1 infection in cell culture. J Mol Genet Med 2009; 3: 217-224.
33. Cheng X, Eisenbraun M, Xu Q, Zhou H, Kulkarni D, Subbarao K et al. H5N1 vaccinespecific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines. PLoS One 2009; 4: e4436.
34. Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008; 3: e2975.
35. Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007; 81: 215-228. (Pubitemid 44975162)
36. Belser JA, Szretter KJ, Katz JM, Tumpey TM. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Adv Virus Res 2009; 73: 55-97.
37. Maines TR, Szretter KJ, Perrone L, Belser JA, Bright RA, Zeng H et al. Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol Rev 2008; 225: 68-84.
38. Yetter RA, Barber WH, Small Jr PA. Heterotypic immunity to influenza in ferrets. Infect Immun 1980; 29: 650-653. (Pubitemid 10040183)
39. Forrest HL, Khalenkov AM, Govorkova EA, Kim JK, Del Giudice G, Webster RG. Singleand multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 2009; 27: 4187-4195.
40. Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 2010; 5: e9106.
41. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009; 83: 5726-5734.
42. Braciale TJ. Immunologic recognition of influenza virus-infected cells. I. Generation of a virus-strain specific and a cross-reactive subpopulation of cytotoxic T cells in the response to type A influenza viruses of different subtypes. Cell Immunol 1977; 33: 423-436.
43. Effros RB, Doherty PC, Gerhard W, Bennink J. Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 1977; 145: 557-568. (Pubitemid 8049609)
44. Doherty PC, Kelso A. Toward a broadly protective influenza vaccine. J Clin Invest 2008; 118: 3273-3275.
45. Liang S, Mozdzanowska K, Palladino G, Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 1994; 152: 1653-1661. (Pubitemid 24075695)
46. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 2001; 183: 368-376. (Pubitemid 32105595)
47. Pichyangkul S, Jongkaewwattana A, Thitithanyanont A, Ekchariyawat P, Wiboon-ut S, Limsalakpetch A et al. Cross-reactive antibodies against avian influenza virus A (H5N1). Emerg Infect Dis 2009; 15: 1537-1539.
48. Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 2008; 180: 1758-1768.
49. Jameson J, Cruz J, Terajima M, Ennis FA. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 1999; 162: 7578-7583. (Pubitemid 29277740)
50. Lee LY, Ha DL, Simmons CP, de Jong MD, Chau NV, Schumacher R et al. Memory T cells established by seasonal human influenza A infection crossreact with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008; 118: 3478-3490.
51. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309: 13-17. (Pubitemid 13062888)
52. Gotch F, McMichael A, Smith G, Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 1987; 165: 408-416. (Pubitemid 17019824)
53. McKinstry KK, Strutt TM, Swain SL. Hallmarks of CD4T cell immunity against influenza. J Intern Med 2011; 269: 507-518.
54. Lynch GW, Selleck P, Sullivan JS. Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza. J Mol Genet Med 2009; 3: 205-209.
55. Hampson AW. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singapore 2008; 37: 510-518.
56. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16: 1389-1391.
57. Epstein SL, Price GE. Cross-protective immunity to influenza A viruses. Expert Rev Vaccines 2010; 9: 1325-1341.
58. Stanekova Z, Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010; 7: 351.
59. Cassone A, Rappuoli R. Universal vaccines: shifting to one for many. MBio 2010; 1: pii: e00042-10.
60. Han T, Marasco WA. Structural basis of influenza virus neutralization. Ann NY Acad Sci 2011; 1217: 178-190.
61. WHO-Human-H5N1 Cumulative cases of H5N1 infections in humans reported to the WHO up to the 8th April 2009. http://www.who.int/csr/disease/avian- influenza/country/en/2009.
62. Smallman-Raynor MC. A.D. avian influenza A (H5N1) age distribution in humans. Emerg Infect Dis 2007; 13: 510-512.
63. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006; 193: 49-53. (Pubitemid 43032498)
64. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. New Engl J Med 2009; 361: 1945-1952.
65. Stelzer-Braid S, Wong B, Robertson P, Lynch GW, O'Brian K, Shaw R et al. Cross-reactive influenza A H3N2 and H1N1 antibodies may give false positive results when using serological tests to determine human H5N1 infection. Clin J Virol 2008; 42: 241-243.
66. Lynch GW, Kapitza N, Fitzgerald A, Walsh B, Sullivan J. The anti-influenza specificities of intravenous immunoglobulins (IVIGs) for targeting human and avian influenza antigens: comparisons of northern and Southern Hemisphere IVIGs. Austr Health Med Res Congr Proc Melbourne Victoria 2006; 5: 467.
67. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324: 246-251.
68. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16: 265-273.
69. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008; 3: e3942.
70. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusic V et al. Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS ONE 2007; 2: e1190.
71. Corti D, Suguitan Jr AL, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120: 1663-1673.
72. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993; 67: 2552-2558. (Pubitemid 23118850)
73. Russell RJ, Gamblin SJ, Haire LF, Stevens DJ, Xiao B, Ha Y et al. H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. Virology 2004; 325: 287-296. (Pubitemid 38902794)
74. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69: 531-569.
75. Wilson IA, Skehel JJ, Wiley DC. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981; 289: 366-373.
76. Tsuchiya E, Sugawara K, Hongo S, Matsuzaki Y, Muraki Y, Li ZN et al. Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus. J Gen Virol 2001; 82: 2475-2484. (Pubitemid 32936780)
77. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4: e59.
78. Boon AC, deBeauchamp J, Krauss S, Rubrum A, Webb AD, Webster RG et al. Crossreactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model. J Virol 2010; 84: 7662-7667.
79. Cancro MP, Hao Y, Scholz JL, Riley RL, Frasca D, Dunn-Walters DK et al. B cells and aging: molecules and mechanisms. Trends Immunol 2009; 30: 313-318.
80. Panda A, Arjona A, Sapey E, Bai F, Fikrig E, Montgomery RR et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol 2009; 30: 325-333.
81. Canaday DH, Amponsah NA, Jones L, Tisch DJ, Hornick TR, Ramachandra L. Influenza-induced production of interferon-alpha is defective in geriatric individuals. J Clin Immunol 2010; 30: 373-383.
82. Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med 2010; 38: e91-e97.
83. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008; 26 (Suppl 4): D35-D40.
84. Ahmed R, Oldstone MB, Palese P. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol 2007; 8: 1188-1193.
85. Rangel-Moreno J, Carragher DM, Misra RS, Kusser K, Hartson L, Moquin A et al. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J Immunol 2008; 180: 454-463.
86. Ansaldi F, Zancolli M, Paolo D, Montomoli E, Sticchi L, Del Giudice G et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010; 28: 4123-4129.
87. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009; 4: e4384.
88. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009; 106: 7962-7967.
89. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172: 5598-5605. (Pubitemid 38542062)
90. Lamb RA, Kug RM. Orthomyxoviridae: The Viruses and Their Replication. In: Knipe DM et al. (eds). Fields Virology, 4th edn, Vol. 2. Lippincott Williams and Wilkins: Philadelphia, USA, 2002.
91. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5: 1157-1163. (Pubitemid 29474420)
92. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004; 22: 2993-3003. (Pubitemid 39037199)
93. Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009; 27: 1440-1447.
94. Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, Nason M et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One 2010; 5: e9812.
95. Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H et al. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol 2010; 155: 535-544.
96. Wu F, Yuan XY, Li J, Chen YH. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine 2009; 27: 4320-4324.
97. Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010; 7: 9.
98. Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z et al. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol J 2010; 7: 151.
99. Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985; 40: 627-633. (Pubitemid 15076578)
100. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci USA 2007; 104: 246-251. (Pubitemid 46068017)
101. Furuse Y, Suzuki A, Kamigaki T, Oshitani H. Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis. Virol J 2009; 6: 67.
102. Furuse Y, Suzuki A, Oshitani H. Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance. Antimicrob Agents Chemother 2009; 53: 4457-4463.
103. Gamblin SJ, Skehel JJ. Influenza haemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 2010; 285: 28403-28409.
104. Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV et al. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol 2006; 151: 921-931.
105. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A novel role for nonneutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008; 181: 4168-4176.
106. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005; 23: 5404-5410. (Pubitemid 41579312)
107. Prokudina EN, Semenova NP. Localization of the influenza virus nucleoprotein: cell-associated and extracellular non-virion forms. J Gen Virol 1991; 72 (Pt 7): 1699-1702.
108. Virelizier JL, Allison AC, Oxford JS, Schild GC. Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells. Nature 1977; 266: 52-54. (Pubitemid 8050009)
109. Yewdell JW, Frank E, Gerhard W. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol 1981; 126: 1814-1819. (Pubitemid 11120964)
110. Zhirnov OP, Isaeva EI, Konakova TE, Thoidis G, Piskareva LM, Akopova II et al. Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Influenza Other Respir Viruses 2007; 1: 71-79.
111. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, Haynes L et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 2011; 85: 5027-5035.
112. Lamere MW, Lam HT, Moquin A, Haynes L, Lund FE, Randall TD et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 2011; 186: 4331-4339.
113. Chen W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008; 105: 17121-17126.
114. Khurana S, Suguitan Jr AL, Rivera Y, Simmons CP, Lanzavecchia A, Sallusto F et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med 2009; 6: e1000049.
115. Miotto O, Heiny A, Tan TW, August JT, Brusic V. Identification of human-to-human transmissibility factors in PB2 proteins of influenza A by large-scale mutual information analysis. BMC Bioinformatics 2008; 9 (Suppl 1): S18.
116. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708-1719.
117. Steel J, Lowen AC, Wang T, Yondola M, Gao Q, Haye K et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010; 1: pii: e00018-10.
118. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329: 1060-1064.
119. Sagawa H, Ohshima A, Kato I, Okuno Y, Isegawa Y. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol 1996; 77: 1483-1487. (Pubitemid 26248662)
120. Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 2008; 3: e2517.
121. Stanekova Z, Kiraly J, Stropkovska A, Mikuskova T, Mucha V, Kostolansky F et al. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Acta Virol 2011; 55: 61-67.
122. Kwong PD, Wilson IA. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 2009; 10: 573-578.
123. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15: 866-870
124. Nguyen T, Davis CT, Stembridge W, Shu B, Balish A, Inui K et al. Characterization of a highly pathogenic avian influenza H5N1 virus sublineage in poultry seized at ports of entry into Vietnam. Virology 2009; 387: 250-256.